Home » Topics » BioWorld Science, Conferences

BioWorld Science, Conferences
RSS

Therapy targeting tumor antigens and immune tolerance evaluated in phase I study

Oct. 5, 2012

Brimonidine improves erythema in patients with rosacea

Oct. 5, 2012

Adalimumab evaluated as a treatment for hidradenitis suppurativa in phase II trial

Oct. 5, 2012

First data on once-weekly DPP IV inhibitor MK-3102 reported

Oct. 4, 2012

Eravacycline compared to ertapenem in patients with intra-abdominal infections

Oct. 4, 2012

Ipragliflozin has beneficial effects in Japanese patients with type 2 diabetes

Oct. 4, 2012

PolyMedix presents new antimicrobials against biowarfare pathogens

Oct. 4, 2012

Intravenous dosing of GSK-322 investigated in healthy subjects

Oct. 4, 2012

Delamanid can be administered with efavirenz

Oct. 3, 2012

PAC-14028 evaluated as a treatment for pruritus

Oct. 3, 2012

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 13, 2026.
AAIC 2026: Age of amyloid is being joined by time of tau
BioWorld
The Alzheimer’s Association International Conference (AAIC) is the world’s biggest dementia conference. And at the AAIC 2026 meeting, there is big buzz around...
Neurovalens granted FDA approval for PTSD therapy for US veterans
BioWorld
Veterans in the U.S. suffering from post-traumatic stress disorder (PTSD) now have access to Neurovalens Ltd.’s Modius Spero, a wearable neuromodulation device,...
NRF2 activators reported in Vailima Peninsula patent
BioWorld Science
Vailima Peninsula Pty Ltd. has discovered new nuclear factor erythroid 2-related factor 2 (NFE2L2; NRF2) activators potentially useful for the treatment of...
News in brief
BioWorld Asia
BioWorld Asia briefs for July 14, 2026